Eachan Johnson

Systems chemical biology for drug discovery


Email
Download CV
PubMed
GitHub

Eachan Johnson

Systems chemical biology for drug disovery

Email
CV
PubMed
GitHub

About

Combining systems biology with cheminformatics, I hope to develop new discovery platforms to quickly find new disease therapies.

Currently, I'm focussed on finding new therapies against Tuberculosis, a disease that kills 1.5 million people per year.

Evolution of pathogenic bacteria in response to drug treatment and the transmissibility of resistance genotypes exhausts the antimicrobial discovery pipeline, causing an unsustainable cycle of drug discovery followed by global resistance. I envision physicians curing infections using personalized, rational, and narrow spectrum combination therapies specifically selected to prevent resistance and minimize patient side effects.

My research interests therefore lie in pursing the answers to these questions:

My broad skills and experience in chemistry, biochemistry, microbiology, and computational biology will be synthesized to harness a holistic chemical genetic paradigm of data-driven systems chemical biology to answer these questions.

Research interests

Chemical biology, quantitative biology and their intersection for therapeutics discovery.

Publications

Preprints

New inhibitors of Mycobacterium tuberculosis identified using systems chemical biology

Johnson EO, LaVerriere E, Stanley M, Office E, et al.

bioRxiv, Aug 2018, 140(7), 2514-2527

doi: 10.1101/396440


Peer-reviewed

A Structural Model of a P450-Ferredoxin Complex from Orientation-Selective Double Electron-Electron Resonance Spectroscopy

Bowen AM, Johnson EO, Mercuri F, Hoskins NJ, Qiao R, et √ďal.

Journal of the American Chemical Society, Feb 2018, 140(7), 2514-2527

PMID: 29266939 | doi: 10.1021/jacs.7b11056


Partial fusion of a cytochrome P450 system by carboxy-terminal attachment of putidaredoxin reductase to P450cam (CYP101A1)

Johnson EO, Wong LL

Catalysis Science and Technology, Sep 2018, 6(20), 7549-7560

PMID: 28944003 | doi: 10.1039/C6CY01042C


Tailoring an alien ferredoxin to support native-like P450 monooxygenase activity

Bell SG, McMillan JH, Yorke JA, Kavanagh E, Johnson EO, Wong LL

Chemical Communications, Dec 2012, 48(95), 11692-11694

PMID: 23104016 | doi: 10.1039/c2cc35968e


Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation

Boehringer J, Riedinger C, Paraskevopoulos K, Johnson EO, Lowe ED, et al.

Biochemical Journal, Nov 2012, 448(1), 55-65

PMID: 22906049 | doi: 10.1042/BJ20120542


The crystal structures of 4-methoxybenzoate bound CYP199A2 and CYP199A4: structural changes on substrate binding and the identification of an anion binding site

Bell SG, Yang W, Tan AB, Zhou R, Johnson EO, et al.

Dalton Transactions, Jul 2012, 41(28), 8703-8714

PMID: 22695988 | doi: 10.1039/c2dt30783a


Selective oxidative demethylation of veratric acid to vanillic acid by CYP199A4 from Rhodopseudomonas palustris HaA2

Bell SG, Tan AB, Johnson EO, Wong LL

Molecular BioSystems, Jan 2010, 6(1), 206-214

PMID: 20024082 | doi: 10.1039/b913487e


Protein recognition in ferredoxin-P450 electron transfer in the class I CYP199A2 system from Rhodopseudomonas palustris

Bell SG, Xu F, Johnson EO, Forward IM, Bartlam M, et al.

Journal of Biological Inorganic Chemistry, Mar 2010, 15(3), 315-28

PMID: 19904564 | doi: 10.1007/s00775-009-0604-7


Crystal structure of a ferredoxin reductase for the CYP199A2 system from Rhodopseudomonas palustris

Xu F, Bell SG, Peng Y, Johnson EO, Bartlam M, et al.

Proteins, Dec 2009, 77(4), 867-880

PMID: 19626710 | doi: 10.1002/prot.22510